12/1
09:23 am
sion
Rating for SION
Medium
Report
Rating for SION
12/1
09:23 am
sion
Rating for SION
Medium
Report
Rating for SION
12/1
08:45 am
sion
Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
Medium
Report
Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
12/1
08:45 am
sion
Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
Medium
Report
Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
12/1
05:37 am
sion
Sionna downgraded to Underperform from Sector Perform at RBC Capital
Medium
Report
Sionna downgraded to Underperform from Sector Perform at RBC Capital
12/1
05:37 am
sion
Sionna downgraded to Underperform from Sector Perform at RBC Capital
Medium
Report
Sionna downgraded to Underperform from Sector Perform at RBC Capital
11/20
06:03 am
sion
Sionna Therapeutics (NASDAQ:SION) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Sionna Therapeutics (NASDAQ:SION) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
08:07 am
sion
Sionna Therapeutics (NASDAQ:SION) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Sionna Therapeutics (NASDAQ:SION) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
11/19
05:12 am
sion
Rating for SION
Low
Report
Rating for SION
11/18
04:17 pm
sion
Sionna Therapeutics initiated with a Buy at BTIG
Low
Report
Sionna Therapeutics initiated with a Buy at BTIG
11/5
02:04 pm
sion
Sionna Therapeutics (NASDAQ:SION) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Sionna Therapeutics (NASDAQ:SION) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..